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Though five patients suffering from subacute bacterial endocarditis were rendered hypokalaemic by 100 mega units of sodium penicillin G daily, there was one patient with coxitis who did not develop any electrolyte disturbance. This suggests that additional factors, such as a tendency to sodium retention (Schwartz et al., 1955) with mild secondary aldosteronism due to clinically apparent or inapparent heart failure or inadequate food intake, form the necessary background for penicillin to cause potassium depletion.
Since patients with subacute bacterial endocarditis often present with heart failure and receive digitalis, it is mandatory to prevent potassium depletion as well as sodium loads. This is easily achieved by substituting the potassium salt of penicillin for the sodium salt. Unfortunately it is more and more difficult to get potassium penicillin G for medical use. The reason for this is probably a largely unjustified fear of inducing potassium intoxication in patients with renal failure. The only instance of fatal potassium intoxication which we were able to find reported in the literature occurred immediately after an obviously too " rapid intravenous administration " of 20 mega units of potassium penicillin G (Thomson, 1964) . In the event of renal failure "massive" therapy with potassium penicillin G must be reduced in order to avoid both the central nervous system toxicity of high serum levels of penicillin and the hyperkalaemia. If potassium penicillin G is not available, potassium depletion and sodium overload may be prevented by combining sodium penicillin with potassium-sparing diuretics like aldactone, triamterene, or amiloride. These drugs block the exchange of sodium for potassium in the distal tubule (Baer et al., 1966; Liddle, 1966) . Consequently the non-reabsorbable anion penicillin is forced to appear in the urine together with the cation sodium and cannot cause or aggravate either congestive heart failure or hypokalaemia.
Summary: Plasma levels of immunoreactive corticotrophin (A.C.T.H.) have been determined in 56 patients with Cushing's syndrome by means of a homologous radioimmunoassay. In untreated Cushing's disease (bilateral adrenal hyperplasia due to excessive A.C.T.H. secretion from the pituitary) plasma values ranged from 40 to 200 jIqtg./ml., between 8 and 10 a.m., compared with a range in normal subjects of 12 to 60 pqtg./ml. Considerably raised levels, often above 2,000 4[tg./ml., were found in patients with Cushing's disease after bilateral adrenalectomy. A.C.T.H. concentrations were usually higher in patients with bilateral adrenal hyperplasia associated with ectopic A.C.T.H. production than in patients with untreated Cushing's disease; whereas plasma A.C.T.H. was undetectable in the presence of an adrenocortical tumour.. All patients with Cushing's syndrome failed to show the normal circadian rhythm of circulating A.C.T.H. levels.
Introduction
Cushing's syndrome, unless due to corticosteroid therapy, is the result of increased cortisol secretion from either an adrenocortical tumour or bilateral adrenocortical hyperplasia. On the basis of bioassay data it appears that circulating A.C.T.H. is undetectable in the plasma of patients with Cushing's syndrome associated with an adrenal adenoma or carcinoma, whereas patients with bilateral adrenal hyperplasia have high normal or raised values (Clayton, 1958; Williams et al., 1961; Vance et al., 1962 ; Ney et al., 1963; Davies, 1964 ; Nelson and Sprunt, 1965 ; Retiene et al., 1965 ; Nelson et al., 1966) . The determination of plasma A.C.T.H. levels is therefore of value in differentiating between the various causes of Cushing's syndrome.
Despite their specificity, bioassays for A.C.T.H. are technically complex and time-consuming and require large volumes of blood to obtain accurate results. The recent introduction of radioimmunoassays for this hormone (Yalow et al., 1964; Demura et al., 1966; Orth et al., 1968) enables circulating levels to be determined more simply by using between 1 and 10 ml. of plasma. Large numbers of subjects can be studied, with serial determinations in individual patients. It should be noted, however, that whereas bioassay determines only biologically active A.C.T.H., immunoassay may also be influenced by biologically inactive fragments (Imura et al., 1965 ; Fleischer et al., 1966 ; Plasma levels of immunoreactive A.C.T.H. were determined as reported previously , and plasma corticosteroid values (as 1 1-hydroxycorticoids) were determined by a fluorimetric procedure (Mattingly, 1962) .
Results
Basal plasma levels of immunoreactive A.C.T.H. between 8 and 10 a.m. are shown in Fig. 1 juyg./ml.) and only 6 of the 20 had basal plasma levels of more than 100 1ltug./ml. Basal values were markedly raised in patients whose Cushing's disease had been treated by total bilateral adrenalectomy, with the exception of one with a level of only 75 t/iLg./ml. (but this plasma had been stored, deep frozen, for more than two years before assay). The five post-adrenalectomy patients with radiological evidence of a pituitary tumour had levels over 900 ,ulug./ml. All five patients with adrenal tumours had undetectable plasma levels of immunoreactive A.C.T.H. (less than 10 /ittg./ml.), whereas the 15 patients with Cushing's syndrome associated with a nonadrenal carcinoma had raised levels usually in excess of 200 ptutg./ml. In the patients with bilateral adrenal hyperplasia A.C.T.H. levels appeared to vary with the severity of the disease, and in untreated Cushing's disease correlated closely with the plasma corticosteroid values (Fig. 2) . Deviation from this correlation occurred in those patients with an ectopic site of A.C.T.H. production who had very high plasma A.C.T.H. concentrations in excess of those necessary to induce a maximum adrenocortical response.
A characteristic feature of all patients with Cushing's syndrome was the absence of a circadian rhythm of plasma A.C.T.H. (see Fig. 3 ). Thus the values found at midnight and midday were similar to the basal morning levels, whereas in a small group of five control subjects the midnight levels had fallen to 10 ,utug./ml. or less.
Discussion
In patients with untreated Cushing's disease basal morning A.C.T.H. levels lie within or slightly above the upper normal range, but after total bilateral adrenalectomy much higher levels are found, often in excess of 2,000 tuqg./ml. Our (Ney et al., 1963; Retiene et al., 1965 often in excess of 200 tt,4g./ml. This latter finding is consistent with the markedly raised cortisol secretion rates and plasma and urinary corticosteroid levels which characterize this condition, and with the clinical observation that many of these patients become pigmented (Liddle et al., 1965 Ney et al. (1963) , that there is a close correlation between both plasma and urinary corticosteroid levels and circulating A.C.T.H. values in patients with pituitary-dependent adrenal hyperplasia, suggest that, provided adrenal function is normal, each corticosteroid determination can be looked on as a bioassay for A.C.T.H. Consequently it is now our custom to restrict the number of A.C.T.H. assays on each patient suspected of having Cushing's syndrome to two morning samples. These levels will help to differentiate between A.C.T.HI.-dependent adrenocortical hyperplasia and an autonomous tumour. Establishment of the diagnosis of the syndrome itself, however, is based on circadian rhythm studies and standard procedures such as the insulin hypoglycaemia and dexamethasone suppression tests (James et al., 1968) which use urinary and/or plasma corticosteroid determinations, since these are easier and more accurate than A.C.T.H. assays.
